Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page
- CheckyesterdayChange DetectedThe page revision label updated from v3.6.2 to v3.6.3, indicating a new version of the page or its underlying system. This update does not alter the study details or other content presented.SummaryDifference0.0%

- Check8 days agoChange DetectedA new page revision tag v3.6.2 was added and the previous v3.6.0 tag removed, indicating a minor update to the page's revision history.SummaryDifference0.0%

- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedNew navigation/help items were added, including Check who can join, Find Contact Information, How to Read a Study Record, Common Questions, and How to Join a Study, and the Intervention/Treatment heading was standardized (Intervention / Treatment vs Intervention/Treatment). The page revision tag was updated from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check29 days agoChange DetectedFooter revision tag updated from v3.5.4 to v3.5.5, indicating a new site version.SummaryDifference0.0%

- Check51 days agoChange DetectedA new revision entry (v3.5.4) was added to the page, replacing the previous revision (v3.5.3) in the study record’s history.SummaryDifference0.0%

- Check72 days agoChange DetectedClinicalTrials.gov’s study page footer was updated to reflect a new site revision version (v3.5.3 instead of v3.5.2), with no visible change to the trial’s study details.SummaryDifference0.0%

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.